This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Leukemia Open Access 24 September 2019
Scientific Reports Open Access 30 September 2015
Chinese Journal of Cancer Open Access 14 September 2015
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Livingston, D.M. Cell 49, 577 (1987).
Druker, B.J., Mamon, H.J. & Roberts, T.M. N. Engl. J. Med. 321, 1383–1391 (1989).
Druker, B.J. et al. Nat. Med. 2, 561–566 (1996).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Druker, B.J. et al. N. Engl. J. Med. 355, 2408–2417 (2006).
O'Brien, S.G. et al. Blood 112 (ASH Annual Meeting Abstracts), 186 (2008).
Druker, B.J. Blood 112, 4808–4817 (2008).
Engelman, J.A. et al. Nat. Med. 14, 1351–1356 (2008).
Fong, P.C. et al. N. Engl. J. Med. 361, 123–134 (2009).
O'Shaughnessy, J. et al. J. Clin. Oncol. 27 (Suppl), 3 (2009).
Cancer Genome Atlas Research Network. Nature 455, 1061–1068 (2008).
Jones, S. et al. Science 321, 1801–1806 (2008).
Parsons, D.W. et al. Science 321, 1807–1812 (2008).
Dilts, D.M. et al. J. Clin. Oncol. 26 (Suppl), 6543 (2008).
Ramsey, S. & Scoggins, J. Oncologist 13, 925–929 (2008).
Dilts, D.M. et al. J. Clin. Oncol. 24, 4553–4557 (2006).
Blanke, C.D. et al. J. Clin. Oncol. 26, 620–625 (2008).
Hodi, F.S. et al. J. Clin. Oncol. 26, 2046–2051 (2008).
Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).
Paez, J.G. et al. Science 304, 1497–1500 (2004).
Kwak, E.L. et al. J. Clin. Oncol. 27 (Suppl), 3509 (2009).
Flaherty, K. et al. J. Clin. Oncol. 27 (Suppl), 9000 (2009).
Johnston, S.R. Clin. Breast Cancer 9, S28–S36 (2009).
The Italian Cooperative Study Group On Chronic Myeloid Leukemia. N. Engl. J. Med. 330, 820–825 (1994).
I am indebted to my wife Alexandra and children, Holden, Julia and Claire for their love and support and the balance they provide to my life. I am extremely appreciative of the assistance from A. Hardy on the writing of this manuscript. This award was made possible by the hundreds of people who have assisted me in my career. This includes all of my current and former laboratory staff, my colleagues and mentors at Oregon Health & Science University, the clinical faculty, and our nurses and data managers. I would like to thank my mentors from the Dana-Farber Cancer Institute and the dedicated scientific and clinical staff at Novartis, who shepherded imatinib through clinical trials. I would also like to thank the numerous investigators who enrolled subjects on our clinical trials. During this time, I have been supported by various funding agencies, including the National Cancer Institute, the Leukemia and Lymphoma Society, the Burroughs Wellcome Fund, the T.J. Martell Foundation, the Doris Duke Charitable Foundation, and the American Cancer Society and the Howard Hughes Medical Institute. I am grateful for this support. Lastly, I would like to thank my patients who have gone on this incredible journey with me.
About this article
Cite this article
Druker, B. Perspectives on the development of imatinib and the future of cancer research. Nat Med 15, 1149–1152 (2009). https://doi.org/10.1038/nm1009-1149
This article is cited by
Nature Reviews Cancer (2016)
Chinese Journal of Cancer (2015)
Scientific Reports (2015)
Cancer research in need of a scientific revolution: Using ‘paradigm shift’ as a method of investigation
Journal of Biosciences (2015)